Patent expiry pembrolizumab-ba.de?

Question

Accepted Answer

Pembrolizumab (Keytruda®) – a PD‑1‑blocking monoclonal antibody developed by Merck & Co. – is protected by a bundle of patents that cover the antibody itself, its production methods, and specific therapeutic uses. Because the patents were filed in the 2000s, the expiration dates vary by claim and by jurisdiction.

1. United States

Category	Typical expiration date	Notes
Composition‑of‑Matter (CoM) patents – e.g., US 9,441,717 “PD‑1‑blocking antibody”	2027 (10‑year term from priority date 2011)	Covers the specific Fab region and affinity‑enhancing mutations.
Use‑patents – e.g., “Use of pembrolizumab for treatment of melanoma”	2031 (10‑year term from filing 2011, or 20‑year term from earliest priority 2009, whichever is longer)	Covers specific cancer indications such as melanoma, NSCLC, etc.
Biosimilar‑related patents (e.g., manufacturing process)	2028–2033	Protects the proprietary cell‑line and process.
Method‑of‑administration patents	2032	Claims on specific dosing regimens or combinations.

Bottom line for the U.S.: The earliest patents that would open the field for generic (or biosimilar) competition are due to expire between 2027 and 2031.

2. European Union

Category	Typical expiration date	Notes
CoM patents	2025	The EU granted a 10‑year term from the earliest priority date (2009).
Use‑patents	2028–2030	Depending on the specific indication and filing date.
Biosimilar‑related patents	2026–2032	Covers cell‑line and process claims.

Bottom line for the EU: The first U.S.‑style “generic” entry could happen as early as 2025 for the antibody itself, with broader use‑patent freedom arriving in 2028‑2030.

3. Other major markets

Region	Typical expiration window	Remarks
Canada	2026–2031	Patent terms align with Canadian Patent Act (20 yr from earliest priority).
Japan	2027–2033	Patents filed 2009–2011; Japan also grants 20‑yr terms.
Australia	2026–2030	20‑yr terms from priority date.

Practical Implications

What it means	What it means
Commercial generics	Generic (biosimilar) manufacturers must wait until the relevant CoM and use patents expire or obtain licenses.
Biosimilars	Some biosimilar companies have already launched products in the U.S. that rely on exclusivity granted by the FDA’s “biosimilar” pathway, which is separate from patent expiry.
Pricing and access	Even after patents expire, the manufacturer may retain marketing exclusivity (e.g., in the U.S. “patent‑beyond‑patent” period) that can delay lower‑priced competition.
Licensing	Many companies hold “secondary” patents (e.g., manufacturing, formulation) that can prolong commercial protection.

How to Check the Exact Dates

USPTO Patent Full‑Text and Image Database (PatFT)
Search for “pembrolizumab” or the relevant patent numbers (e.g., US 9,441,717) to view the filing, priority, and expiration dates.
European Patent Office (EPO) Espacenet
Use the “Search by Publication Number” feature or “Search by Inventor” to locate the EU‑specific patents and see their term.
World Intellectual Property Organization (WIPO) PATENTSCOPE
Allows you to view international applications (PCT) and the corresponding national phase dates.

Bottom‑Line Summary

U.S.: Key patents for the antibody itself expire 2027; use‑patents expire 2031.
EU: Antibody‑composition patents expire 2025; broader use claims expire 2028–2030.
Other jurisdictions: Similar 20‑year terms from 2009–2011 priority dates, usually ending 2026–2033.

If you’re involved in a clinical trial, regulatory submission, or commercial strategy, it’s wise to confirm the specific claims that apply to your jurisdiction and consider whether any “secondary” patents (process, formulation, packaging) could extend exclusivity.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Patent expiry pembrolizumab-ba.de?

1. United States

2. European Union

3. Other major markets

Practical Implications

How to Check the Exact Dates

Bottom‑Line Summary